114 related articles for article (PubMed ID: 22803620)
1. Tuberculosis after anti-TNF therapy: a continuous learning process.
Psichogiou M; Sfikakis PP; Kontos F; Daikos GL
Scand J Rheumatol; 2012 Oct; 41(5):401-3. PubMed ID: 22803620
[No Abstract] [Full Text] [Related]
2. Late onset tuberculosis infection in patients receiving anti-TNFα therapy.
Mongey AB; Doran JP; Kleinerova J; Fitzgerald O; McDonnell TJ
QJM; 2014 Jan; 107(1):69-71. PubMed ID: 23970181
[No Abstract] [Full Text] [Related]
3. Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy.
Lahita RG; Vernace MA
J Rheumatol; 2011 Mar; 38(3):579-80. PubMed ID: 21362795
[No Abstract] [Full Text] [Related]
4. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
5. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
6. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
Denis B; Lefort A; Flipo RM; Tubach F; Lemann M; Ravaud P; Salmon D; Mariette X; Lortholary O;
Clin Microbiol Infect; 2008 Feb; 14(2):183-6. PubMed ID: 18076664
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
9. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
10. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
11. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
[No Abstract] [Full Text] [Related]
12. Erythema nodosum, a "red flag" during anti-TNF therapy.
Dalmau-Carolà J
Int J Rheum Dis; 2013 Aug; 16(4):493-4. PubMed ID: 23992277
[No Abstract] [Full Text] [Related]
13. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
[No Abstract] [Full Text] [Related]
14. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
15. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy.
Taylor JC; Orkin R; Lanham J
Rheumatology (Oxford); 2003 Jul; 42(7):901-2. PubMed ID: 12826707
[No Abstract] [Full Text] [Related]
17. Trouble with tumor necrosis factor alpha inhibitors, not just tuberculosis.
Racunica T; Cassidy D; Cicuttini F; Hall A
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):770-4. PubMed ID: 20535787
[No Abstract] [Full Text] [Related]
18. Optic neuritis in a psoriatic arthritis patient treated by infliximab.
Minami-Hori M; Tsuji H; Takahashi H; Hanada K; Iizuka H
J Dermatol; 2013 Apr; 40(4):298-9. PubMed ID: 23289758
[No Abstract] [Full Text] [Related]
19. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
20. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Sieper J; Emery P; Keystone EC; Schiff MH; Mease P; van Riel PL; Fleischmann R; Weisman MH; Weinblatt ME
Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
